Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: results from the randomised ARTFORCE PET-boost trial
Authors
Cooke, S. A.Belderbos, J. S. A.
Reymen, B.
Lambrecht, M.
Fredberg Persson, G.
Faivre-Finn, Corinne
Dieleman, E. M. T.
van Diessen, J. N. A.
Sonke, J. J.
de Ruysscher, D.
Affiliation
Department of Clinical Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: The ultimate challenge in dose-escalation trials lies in finding the balance between benefit and toxicity. We examined patient-reported outcomes (PROs), including health-related quality of life (HRQoL) in patients with locally advanced non-small cell lung cancer (LA-NSCLC), treated with dose-escalated radiotherapy. MATERIALS AND METHODS: The international, randomised, phase 2 ARTFORCE PET-Boost study (NCT01024829) aimed to improve 1-year freedom from local failure rates in patients with stage II-III NSCLC, with a ≥ 4 cm primary tumour. Treatment consisted of an individualised, escalated fraction dose, either to the primary tumour as a whole or to its most FDG-avid subvolume (24 x 3.0-5.4 Gy). Patients received sequential or concurrent chemoradiotherapy, or radiotherapy only. Patients were asked to complete the EORTC QLQ-C30, QLQ-LC13, and the EuroQol-5D at eight timepoints. We assessed the effect of dose-escalation on C30 sum score through mixed-modelling and evaluated clinically meaningful changes for all outcomes. RESULTS: Between Apr-2010 and Sep-2017, 107 patients were randomised; 102 were included in the current analysis. Compliance rates: baseline 86.3%, 3-months 85.3%, 12-months 80.3%; lowest during radiation treatment 35.0%. A linear mixed-effect (LME) model revealed no significant change in overall HRQoL over time, and no significant difference between the two treatment groups. Physical functioning showed a gradual decline in both groups during treatment and at 18-months follow-up, while clinically meaningful worsening of dyspnoea was seen mainly at 3- and 6-months. CONCLUSION: In patients with LA-NSCLC treated with two dose-escalation strategies, the average patient-reported HRQoL remained stable in both groups, despite frequent patient-reported symptoms, including dyspnoea, dysphagia, and fatigue.Citation
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, et al. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024 Jul;196:110312. PubMed PMID: 38663582. Epub 2024/04/26. eng.Journal
Radiotheraphy OncologyDOI
10.1016/j.radonc.2024.110312PubMed ID
38663582Additional Links
https://dx.doi.org/10.1016/j.radonc.2024.110312Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2024.110312
Scopus Count
Collections
Related articles
- (18)F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial.
- Authors: Cooke SA, de Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, Lewensohn R, van Diessen JNA, Sikorska K, Lalezari F, Vogel W, van Elmpt W, Damen EMF, Sonke JJ, Belderbos JSA
- Issue date: 2023 Apr
- Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
- Authors: Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P
- Issue date: 2024 Sep
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
- Authors: Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
- Issue date: 2019 Dec
- The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
- Authors: van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J
- Issue date: 2019 Feb
- Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.
- Authors: Hallqvist A, Bergman B, Nyman J
- Issue date: 2012 Jul